Literature DB >> 31699903

Association Between Skin Reaction and Clinical Benefit in Patients Treated with Anti-Programmed Cell Death 1 Monotherapy for Advanced Non-Small Cell Lung Cancer.

Mari Aso1, Yukihiro Toi1, Jun Sugisaka1, Tomoiki Aiba1, Sachiko Kawana1, Ryohei Saito1, Takahiro Ogasawara1, Kyoji Tsurumi1, Kana Ono1, Hisashi Shimizu1, Yutaka Domeki1, Keisuke Terayama1, Yosuke Kawashima1, Atsushi Nakamura1, Shinsuke Yamanda1, Yuichiro Kimura1, Yoshihiro Honda1, Shunichi Sugawara2.   

Abstract

BACKGROUND: Anti-programmed cell death 1 antibody is a standard therapy for advanced non-small cell lung cancer (NSCLC). However, immune-related adverse events (irAEs), such as skin reactions, are frequently observed. Although skin reactions are associated with clinical efficacy in melanoma, this association in advanced NSCLC and predictors of irAEs remain unclear. Accordingly, this study identified potential correlations of skin reactions with clinical efficacy and clinical predictors of development of skin reactions. SUBJECTS, MATERIALS, AND METHODS: We retrospectively surveyed patients with advanced NSCLC who received nivolumab or pembrolizumab monotherapy at Sendai Kousei Hospital (n = 155) during January 2016 to April 2018. Treatment efficacy was evaluated in patients with and without skin reactions, and associated predictive markers were determined. A 6-week landmark analysis was conducted to assess the clinical benefit of early skin reactions.
RESULTS: Skin reactions were observed in 51 patients with a median time to onset of 6.4 weeks. The overall response rate (ORR) was significantly higher in patients with skin reactions (57% vs. 19%, p < .001). Median progression-free survival (PFS) durations of 12.9 and 3.5 months and overall survival durations of not reached and 11.4 months were observed in patients with and without skin reactions, respectively. In the 6-week landmark analysis, the ORR was significantly higher in patients with skin reactions, and skin reactions were significantly associated with increased PFS. A multivariate analysis identified pre-existing rheumatoid factor (RF) as an independent predictor of skin reactions.
CONCLUSION: Skin reactions appeared beneficial in patients treated with nivolumab/pembrolizumab for advanced NSCLC and could be predicted by pre-existing RF. Further large-scale validations studies are warranted. IMPLICATIONS FOR PRACTICE: This single-institutional medical record review that included 155 patients with advanced non-small cell lung cancer who were treated with nivolumab or pembrolizumab monotherapy revealed that overall response rate and progression-free survival were significantly better in patients with skin reactions. Pre-existing rheumatoid factor was an independent predictor of skin reactions. © AlphaMed Press 2019.

Keywords:  Immune‐related adverse events; Immunotherapy; Lung cancer; Programmed cell death 1; Rheumatoid factor; Skin reaction

Year:  2019        PMID： 31699903     DOI： 10.1634/theoncologist.2019-0550

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


  32 in total

1.  The inhibitory receptor PD-1 regulates IgA selection and bacterial composition in the gut.

Authors:  Shimpei Kawamoto; Thinh H Tran; Mikako Maruya; Keiichiro Suzuki; Yasuko Doi; Yumi Tsutsui; Lucia M Kato; Sidonia Fagarasan
Journal:  Science       Date:  2012-04-27       Impact factor: 47.728

2.  PD-1 is a novel regulator of human B-cell activation.

Authors:  Marie-Laure Thibult; Emilie Mamessier; Julie Gertner-Dardenne; Sonia Pastor; Sylvaine Just-Landi; Luc Xerri; Bruno Chetaille; Daniel Olive
Journal:  Int Immunol       Date:  2012-10-18       Impact factor: 4.823

3.  Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.

Authors:  Achim Rittmeyer; Fabrice Barlesi; Daniel Waterkamp; Keunchil Park; Fortunato Ciardiello; Joachim von Pawel; Shirish M Gadgeel; Toyoaki Hida; Dariusz M Kowalski; Manuel Cobo Dols; Diego L Cortinovis; Joseph Leach; Jonathan Polikoff; Carlos Barrios; Fairooz Kabbinavar; Osvaldo Arén Frontera; Filippo De Marinis; Hande Turna; Jong-Seok Lee; Marcus Ballinger; Marcin Kowanetz; Pei He; Daniel S Chen; Alan Sandler; David R Gandara
Journal:  Lancet       Date:  2016-12-13       Impact factor: 79.321

4.  A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC.

Authors:  A Lisberg; A Cummings; J W Goldman; K Bornazyan; N Reese; T Wang; P Coluzzi; B Ledezma; M Mendenhall; J Hunt; B Wolf; B Jones; J Madrigal; J Horton; M Spiegel; J Carroll; J Gukasyan; T Williams; L Sauer; C Wells; A Hardy; P Linares; C Lim; L Ma; C Adame; Edward B Garon
Journal:  J Thorac Oncol       Date:  2018-06-01       Impact factor: 15.609

5.  Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor.

Authors:  H Nishimura; M Nose; H Hiai; N Minato; T Honjo
Journal:  Immunity       Date:  1999-08       Impact factor: 31.745

6.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

Authors:  E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij
Journal:  Eur J Cancer       Date:  2009-01       Impact factor: 9.162

7.  Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression.

Authors:  Martina Sanlorenzo; Igor Vujic; Adil Daud; Alain Algazi; Matthew Gubens; Sara Alcántara Luna; Kevin Lin; Pietro Quaglino; Klemens Rappersberger; Susana Ortiz-Urda
Journal:  JAMA Dermatol       Date:  2015-11       Impact factor: 10.282

8.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

9.  Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes.

Authors:  Morganna Freeman-Keller; Youngchul Kim; Heather Cronin; Allison Richards; Geoffrey Gibney; Jeffrey S Weber
Journal:  Clin Cancer Res       Date:  2015-10-07       Impact factor: 12.531

10.  Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab.

Authors:  Yukihiro Toi; Shunichi Sugawara; Yosuke Kawashima; Tomoiki Aiba; Sachiko Kawana; Ryohei Saito; Kyoji Tsurumi; Kana Suzuki; Hisashi Shimizu; Jun Sugisaka; Hirotaka Ono; Yutaka Domeki; Keisuke Terayama; Atsushi Nakamura; Shinsuke Yamanda; Yuichiro Kimura; Yoshihiro Honda
Journal:  Oncologist       Date:  2018-06-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.